PREDILIFE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.7 EUR | -2.19% |
|
-2.90% | +17.54% |
| 2023 | Predilife: a project accredited by Finance Innovation | CF |
| 2023 | Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +17.54% | 27.58M | |
| -41.39% | 8.02B | |
| +3.25% | 3.43B | |
| -0.37% | 2.27B | |
| -19.19% | 2.03B | |
| -22.57% | 1.63B | |
| +32.82% | 1.16B | |
| -8.30% | 703M | |
| +14.12% | 714M | |
| -31.22% | 500M |
- Stock Market
- Equities
- ALPRE Stock
- News PREDILIFE
- Predilife Taps Eurofins to Conduct Genetic Testing of Saliva Samples
